Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppressionThe study which compared MB310, a precision microbiome medicine, with ...

FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...

More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Cholesterol-lowering statins might protect patients with ulcerative colitis from developing and dying from colorectal cancer. Statin treatment was also associated with a lower risk of death regardless ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Wearable devices can identify, ...